Sana Biotechnology Inc Quick Ratio (SANA) starting from the third quarter 2026 to third quarter 2025, Financial Strength Trends, Rankings, Financial Ratios - CSIMarket
CSIMarket Company Name, Ticker, Industry, else..
 


• Quick Ratio
• Working Capital
• LT Debt to Equity
• Debt to Equity
• Leverage Ratio
• Tangible Leverage
• Interest Coverage
• Debt Coverage
• Work. Cap. Per Revenue
Sana Biotechnology Inc   (NASDAQ: SANA)

Sana Biotechnology Inc 's Quick Ratio

SANA's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth


Regardless of the sequential decrease in Current Liabilities, during the third quarter 2026, Quick Ratio deteriorated to 1.63 below Sana Biotechnology Inc 's average Quick Ratio.

Within Biotechnology & Pharmaceuticals industry 81 other companies have achieved higher Quick Ratio than Sana Biotechnology Inc in third quarter 2026. While Quick Ratio total ranking has improved so far during the Q3 2026 to 1087, from total ranking in the second quarter 2026 at 1473.

Explain Quick Ratio?
How much Cash & cash equivalents SANA´s has?
What are SANA´s Current Liabilities?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

SANA Quick Ratio (Sep 30 2026)
Q3		 (Jun 30 2026)
Q2		 (Mar 31 2026)
Q1		 (Dec 31 2025)
Q4		 (Sep 30 2025)
Q3
Y / Y Current Liabilities Change 110.85 % 270.03 % 160.18 % 73.28 % -24.45 %
Y / Y Cash & cash equivalent Change -20.47 % 341.68 % -3.4 % -9.26 % -23.09 %
Quick Ratio MRQ 1.63 2.59 1.17 1.76 4.31
SANA's Total Ranking # 1087 # 1473 # 715 # 409 #
Seq. Current Liabilities Change -39.49 % 43.46 % 9.58 % 121.68 % 6.19 %
Seq. Cash & cash equivalent Change -62.08 % 217.38 % -26.92 % -9.59 % 110.6 %



Quick Ratio third quarter 2026 Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry # 82
Healthcare Sector # 437
Overall Market # 1087


Quick Ratio Statistics
High Average Low
27.32 6.61 1.17
(Mar 31 2021)   (Mar 31 2026)




Financial Statements
Sana Biotechnology Inc 's Current Liabilities $ 75 Millions Visit SANA's Balance sheet
Sana Biotechnology Inc 's Cash & cash equivalent $ 122 Millions Visit SANA's Balance sheet
Source of SANA's Sales Visit SANA's Sales by Geography


Cumulative Sana Biotechnology Inc 's Quick Ratio

SANA's Quick Ratio for the trailling 12 Months

SANA Quick Ratio

 (Sep 30 2026)
12 Months		 (Jun 30 2026)
12 Months		 (Mar 31 2026)
12 Months		 (Dec 31 2025)
12 Months		 (Sep 30 2025)
12 Months
Y / Y Current Liabilities TTM Growth 146.45 % 103.89 % 32.71 % -7.75 % -31.4 %
Y / Y Cash & cash equivalent TTM Growth 41.27 % 34.92 % -34.27 % -48.72 % -50.06 %
Quick Ratio TTM 1.88 2.2 1.99 2.59 3.27
Total Ranking TTM # 3869 # 2876 # 2022 # 1972 #
Seq. Current Liabilities TTM Growth 12.14 % 38.6 % 29.37 % 22.56 % -7.23 %
Seq. Cash & cash equivalent TTM Growth -4.39 % 53.37 % -0.76 % -2.92 % -8.69 %

Quick ratio ranking by company, industry and sector >> Back to SANA Financial Strength Comparisons >> Go to Compare SANA Quick Ratio to its Competitors

On the trailing twelve months basis Due to cut in Current Liabilities in the Q3 2026 to $74.88 millions, cumulative Quick Ratio decreased to 1.88 below the Sana Biotechnology Inc average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Biotechnology & Pharmaceuticals industry 141 other companies have achieved higher Quick Ratio than Sana Biotechnology Inc . While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the second quarter 2026 from 2876 to 3869.

Explain Quick Ratio?
How much Cash & cash equivalents SANA´s has?
What are SANA´s Current Liabilities?

TTM Quick Ratio Company Ranking
Within: No.
Within the Biotechnology & Pharmaceuticals Industry # 142
Healthcare Sector # 885
Within the Market # 3869


trailing twelve months Quick Ratio Statistics
High Average Low
11.02 4.38 0.01
(Dec 31 2021)   (Mar 31 2021)




Companies with similar Quick Ratio in the quarter ending Sep 30 2026, within Biotechnology & Pharmaceuticals Industry Quick RatioSep 30 2026 MRQ Cash & cash equivalentSep 30 2026 MRQ Current Liabilities
Fate Therapeutics Inc   4.26 $ 139.132  Millions$ 32.691  Millions
Kymera Therapeutics Inc   4.16 $ 373.374  Millions$ 89.723  Millions
Monte Rosa Therapeutics Inc   4.16 $ 577.726  Millions$ 139.022  Millions
Vir Biotechnology Inc   4.08 $ 454.635  Millions$ 111.332  Millions
Moderna Inc   3.93 $ 7,976.000  Millions$ 2,028.000  Millions
Immunocore Holdings Plc  3.93 $ 901.298  Millions$ 229.619  Millions
Alector Inc   3.92 $ 138.697  Millions$ 35.415  Millions
Dbv Technologies S a   3.89 $ 165.700  Millions$ 42.600  Millions
Regenxbio Inc   3.71 $ 250.976  Millions$ 67.684  Millions
Tenaya Therapeutics Inc   3.55 $ 66.797  Millions$ 18.804  Millions
Intensity Therapeutics Inc   3.29 $ 8.494  Millions$ 2.582  Millions
Adaptive Biotechnologies Corporation  3.02 $ 298.954  Millions$ 98.967  Millions
Atyr Pharma Inc   2.96 $ 48.751  Millions$ 16.463  Millions
Precision Biosciences Inc  2.90 $ 81.846  Millions$ 28.258  Millions
Vericel Corporation  2.44 $ 133.493  Millions$ 54.719  Millions
Adma Biologics Inc   2.25 $ 124.555  Millions$ 55.475  Millions
Exelixis Inc   2.17 $ 892.018  Millions$ 411.877  Millions
Halozyme Therapeutics Inc   2.12 $ 1,074.480  Millions$ 506.173  Millions
Relay Therapeutics Inc   2.10 $ 124.184  Millions$ 59.154  Millions
Biocryst Pharmaceuticals Inc   1.92 $ 375.334  Millions$ 195.830  Millions
Novavax inc   1.89 $ 622.363  Millions$ 329.845  Millions
Lenz Therapeutics Inc   1.78 $ 31.610  Millions$ 17.750  Millions
Acumen Pharmaceuticals Inc   1.74 $ 78.604  Millions$ 45.087  Millions
Sana Biotechnology Inc   1.63 $ 121.728  Millions$ 74.880  Millions
Aligos Therapeutics Inc   1.59 $ 31.094  Millions$ 19.600  Millions
Tarsus Pharmaceuticals Inc   1.36 $ 309.612  Millions$ 227.114  Millions
Amgen Inc   1.11 $ 25,811.000  Millions$ 23,231.000  Millions
Sab Biotherapeutics Inc   0.98 $ 14.438  Millions$ 14.798  Millions
Bio techne Corp  0.97 $ 350.036  Millions$ 361.269  Millions
C4 Therapeutics Inc   0.81 $ 33.492  Millions$ 41.460  Millions

Date modified: 2026-11-09T06:47:18+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.